Biogen Stock (BIIB)

XNGS Alert Compare

Health Care · Fundamental analysis

Biogen's revenue has shrunk by 6.0% a year over the last 5 years; the median of the Health Care sector is +8.5%. The net margin in the last fiscal year was 13.1%, the sector median 13.9%. The 52-week high is 4.6% away (close of Nov 20, 2026).

· How we analyze

Metrics from daily candles, as of Nov 20, 2026 · Extended universe

Figures in the price bar from TradingView (mostly trailing 12 months) · our fundamental analysis uses the fiscal year

At a glance: figures and chart

3 strengths · 3 weaknesses · Fiscal year to Dec 31, 2025
Quality checks from the annual figures and, separately, the position of the price relative to the 200-day line. No overall score.
  • Quality 6 of 7 criteria with data met · 1 without data
  • Growth 1 of 7 criteria with data met
  • Dividend 0 of 1 criteria with data met · 6 without data
  • Financial strength 5 of 6 criteria with data met
Chart position more than 10% above – position relative to the 200-day line

Strengths well above the threshold

  • Gross margin 75.7% Threshold: above 40% · Distance +35.7 pp · Sector median 61.8% (49 stocks) · Fiscal year to Dec 31, 2025
  • Free cash flow margin 20.7% Threshold: above 10% · Distance +10.7 pp · Sector median 14.5% (61 stocks) · Fiscal year to Dec 31, 2025
  • Equity ratio 62.0% Threshold: above 30% · Distance +32.0 pp · Sector median 44.2% (63 stocks) · Fiscal year to Dec 31, 2025

Weaknesses well below the threshold

  • Return on equity 7.1% Threshold: above 15% · Distance −7.9 pp · Sector median 12.8% (54 stocks) · Fiscal year to Dec 31, 2025
  • Revenue growth 5 years −6.0% per year Threshold: above 5% per year · Distance −11.0 pp · Sector median +7.8% per year (60 stocks) · Fiscal year to Dec 31, 2025
  • Piotroski F-Score 5 of 9 Threshold: at least 7 · Distance −2 points · Sector median 6 of 9 (47 stocks) · Fiscal year to Dec 31, 2025

On the radar

  • Position relative to the 200-day line: more than 10% above (as of Nov 20, 2026)

What we do not know

  • Data missing: 1 of 28 criteria not stated in the SEC filings (Fiscal year to Dec 31, 2025).
    • Operating margin above 15%

Not applicable

  • Pays no dividend – the dividend criteria do not apply (Fiscal year to Dec 31, 2025).

How is this made? · Created on Nov 22, 2026 from fixed rules · not investment advice

Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Preset: moving averages 50 and 200 (on the daily chart the 50- and 200-day lines), plus volume. You can add further indicators in the chart yourself. Academy: 200-day line · RSI

About the company

Biogen is a biotechnology company from Massachusetts focused on diseases of the nervous system. It offers drugs for multiple sclerosis and spinal muscular atrophy (Spinraza) and markets the Alzheimer’s drug Leqembi with Eisai. As of Oct 11, 2026

Fact sheet (from the annual report) Biotechnology and vaccines · Cambridge, USA

According to the company, the group is a global biopharmaceutical company focused on neurology, specialized immunology and rare diseases. For multiple sclerosis it markets TYSABRI, TECFIDERA, VUMERITY and AVONEX, and for spinal muscular atrophy SPINRAZA. Other products are SKYCLARYS for Friedreich’s ataxia and QALSODY for a genetic form of ALS. Together with Eisai the group markets LEQEMBI for a form of dementia and, with Supernus, the drug ZURZUVAE. TYSABRI and SPINRAZA each accounted for a material share of total revenue in 2025. In November 2025 the group acquired Alcyone Therapeutics, and in 2025 it gave up its rights to TOFIDENCE and BYOOVIZ.

Automatically summarized from SEC annual report (10-K, filed Feb 6, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

What the methods say about Biogen

This symbol belongs to the extended universe: we load daily candles only and show metrics, fundamentals and an overview – chart methods and Elliott analysis are not available for it.

Calculated automatically by fixed rules – not investment advice, check for yourself. How we analyze

Price performance at a glance

Last 30 trading days
  • Today +1.0%
  • 7 days −1.5%
  • 30 days +3.6%
  • 1 year +48.4%
Day range (last trading day)
−0.6%Price at 31% of the range+1.4%
52-week range
−35.8%Price at 89% of the range+4.6%
Distance from the all-time high
−48.0%

Our own calculation from the exchange’s daily candles, as of Nov 20, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Chart analysis: trend by timeframe

  1. 1W weekly candles up
    • Close above the SMA 200
    • EMA 20 above the EMA 50
    • higher highs and higher lows

    Price above the EMA 20 · above the EMA 50

    Week to Nov 20, 2026

  2. 1D daily candles mixed
    • Close above the SMA 200
    • EMA 20 above the EMA 50
    • lower highs and lower lows

    Price above the EMA 20 · above the EMA 50

    Daily candle of Nov 20, 2026

  3. 4H 4-hour candles not available

    No value on 4 hours (too few or no checked 4-hour candles).

Rule per timeframe: up = close above the SMA 200, EMA 20 above the EMA 50 and higher highs and lows; down = everything the other way round; otherwise mixed. Completed candles only, no overall score, no forecast. In the screener: all three up

What does the daily chart show right now – line by line, without an overall verdict?

Technicals in plain words

Over the last 3 months it ran stronger than the S&P 500 and stronger than the median of the sector “Health Care”.

vs. S&P 500 · 3 months
stronger
vs. S&P 500 · 6 months
stronger
vs. sector · 3 months
stronger
  • Trend above SMA 200 Price above the 200-day line – above it the long-term trend counts as up; ADX between 20 and 25 – a moderate trend.
  • Momentum neutral RSI between 30 and 70 – neither overbought nor oversold; MACD line below its signal line (gap below 0).
  • Volume not elevated Volume on the last trading day below 1.5 times the average of up to 50 trading days before – not elevated.
  • Volatility normal Typical daily range (ATR 14) between 2 and 4% of the price – normal; Bollinger Bands as narrow as on at most one fifth of the last 120 trading days (squeeze).

The figures behind it – distance to the line, RSI, volume, volatility and relative strength in percentage points – are visible with a free account. Sign up free

More depth

How we read the lines

  • Each line stands on its own – we do not add them up and give no grade.
  • Trend: the 200-day line is the average of the last 200 closing prices. The ADX (14) measures how pronounced a trend is, not its direction: below 20 hardly any trend, above 25 pronounced.
  • Momentum: the RSI (14) lies between 0 and 100; below 30 it counts as oversold, above 70 as overbought. The MACD (12/26) compares two averages, the signal line (9) smooths it.
  • Volume: shares traded on the last trading day divided by the average of up to 50 trading days before; from 1.5x elevated, from 2x unusually high, from 3x very high.
  • Volatility: typical daily range (ATR 14) as a percentage of the price; below 2% calm, 2 to 4% normal, above 4% high. Squeeze = Bollinger Bands as narrow as on at most a fifth of the last 120 trading days.
  • Relative strength: the stock’s price change minus that of the benchmark over the same period (3 months = 91 days, 6 months = 182 days), in percentage points, from completed daily candles. Benchmark: the S&P 500 (ETF SPY) or the median of the stocks of the same sector in our selection (at least 5 others with a candle on the same day). Dividends are not included.
  • Against the sector median over 6 months: ran stronger.
  • All figures describe the price history so far – they do not say what happens next.

In the screener: stocks that ran stronger than the S&P 500 over 3 months

As of: daily candle of Nov 20, 2026 · from our daily candles

How did this asset do in each calendar month over the last 10 years?

Seasonality

In November, the stock closed higher in 6 of 10 years – the S&P 500 in 9 of 10.

Years higher in November
6 of 10
2016 to 2025
S&P 500 in November
9 of 10
years higher, same years as above (ETF SPY)
Months mostly higher
5 of 12
Calendar months that closed higher in more than half of the years

You can see the median and range per month in percent with a free account. Sign up free

  • January: higher in 5 of 10 years
  • February: higher in 3 of 10 years
  • March: higher in 3 of 10 years
  • April: higher in 2 of 10 years
  • May: higher in 6 of 10 years
  • June: higher in 6 of 10 years
  • July: higher in 6 of 10 years
  • August: higher in 6 of 10 years
  • September: higher in 4 of 10 years
  • October: higher in 4 of 10 years
  • November (current month): higher in 6 of 10 years
  • December: higher in 3 of 10 years
Past performance, not a forecast · Bar = share of years higher, line = half · Price return without dividends
More depth

How we calculate

  • Monthly return = closing price on the last trading day of the month ÷ closing price on the last trading day of the previous month − 1. Price return without dividends.
  • Only completed months count, never the current one. If the candle of the last trading day is missing, the month does not count.
  • For each calendar month the last 10 years in which it has ended; from 8 years with a value we show the median, years higher and the range. “Higher” means: return above 0.0%.
  • Past performance, not a forecast: the figures describe earlier years and do not tell how the next month will go.
By calendar month (● = current month)
MonthYears higher
January5 of 10
February3 of 10
March3 of 10
April2 of 10
May6 of 10
June6 of 10
July6 of 10
August6 of 10
September4 of 10
October4 of 10
November ●6 of 10
December3 of 10

Through October 2026 (last completed month) · from our daily candles

Fundamental analysis

Biogen · Sector Health Care · amounts in USD

Source: SEC filings, As of Feb 6, 2026.

For you first Dividend

The company pays no dividend.

For you first Valuation

The P/E is above its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

For you first Growth

How strongly revenue and earnings per share have grown over the years.

Check “Growth”
1 of 7
criteria with data met
Revenue per year (5 y)
−6.0%
EPS per year (5 y)
−18.7%

For you first Quality

How much of revenue remains and whether profit arrives as cash.

Check “Quality”
6 of 7
criteria with data met
Net margin
13.1%
Cash flow ÷ profit
1.71x
backed from 1.0 · 3 years: 1.62x

For you first Trading

Trend by timeframe under a fixed rule – direction, not a forecast.

weekly candles
up
daily candles
mixed

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality 6 of 7 met · 1 without data

  • met: Gross margin above 40% 75.7%
  • no data: Operating margin above 15% not stated in the SEC filings
  • met: Net margin above 10% 13.1%
  • not met: Return on equity above 15% 7.1%
  • met: Free cash flow margin above 10% 20.7%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • met: Equity ratio above 30% 62.0%
Gross margin

75.7% Fiscal year 2025

Rank 89 of 100: higher than 89% of 370 peers (All). strong.

Rank 89 of 100: higher than 89% of 49 peers (Sector). strong.

Median Health Care: 61.8%

Share of revenue left after the direct cost of the products sold.

Net margin

13.1% Fiscal year 2025

Rank 56 of 100: higher than 56% of 584 peers (All). medium.

Rank 52 of 100: higher than 52% of 63 peers (Sector). medium.

Median Health Care: 12.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

7.1% Fiscal year 2025

Rank 26 of 100: higher than 26% of 544 peers (All). weak.

Rank 25 of 100: higher than 25% of 54 peers (Sector). weak.

Median Health Care: 12.8%

Net income divided by equity at fiscal year end.

Return on assets

4.4% Fiscal year 2025 (total assets at year end)

Rank 45 of 100: higher than 45% of 594 peers (All). medium.

Rank 36 of 100: higher than 36% of 63 peers (Sector). medium.

Median Health Care: 6.6%

Net income divided by total assets at fiscal year end.

Equity ratio

62.0% Fiscal year 2025

Rank 85 of 100: higher than 85% of 595 peers (All). strong.

Rank 75 of 100: higher than 75% of 63 peers (Sector). strong.

Median Health Care: 44.2%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

20.7% Fiscal year 2025

Rank 78 of 100: higher than 78% of 465 peers (All). strong.

Rank 70 of 100: higher than 70% of 61 peers (Sector). strong.

Median Health Care: 14.5%

Free cash flow divided by revenue.

Free cash flow

2.1B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 1 of 7 met

  • not met: Over 3 years, revenue grew by more than 5% per year −0.9%
  • not met: Over 5 years, revenue grew by more than 5% per year −6.0%
  • not met: Over 10 years, revenue grew by more than 5% per year −0.8%
  • not met: Over 3 years, EPS grew by more than 5% per year −25.0%
  • not met: Over 5 years, EPS grew by more than 5% per year −18.7%
  • not met: Revenue rose in at least 4 of the last 5 fiscal years 1 of 5
  • met: Revenue rose in the last fiscal year +2.2%
Revenue growth 3 years

−0.9% per year

Rank 18 of 100: higher than 18% of 578 peers (All). weak.

Rank 15 of 100: higher than 15% of 62 peers (Sector). weak.

Median Health Care: +5.1%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

−6.0% per year

Rank 2 of 100: higher than 2% of 549 peers (All). weak.

Rank 1 of 100: higher than 1% of 60 peers (Sector). weak.

Median Health Care: +7.8%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

−0.8% per year

Rank 5 of 100: higher than 5% of 412 peers (All). weak.

Rank 3 of 100: higher than 3% of 50 peers (Sector). weak.

Median Health Care: +9.3%

Average growth per year over 10 fiscal years.

EPS growth 3 years

−25.0% per year

Rank 9 of 100: higher than 9% of 437 peers (All). weak.

Rank 5 of 100: higher than 5% of 54 peers (Sector). weak.

Median Health Care: +5.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

−18.7% per year

Rank 4 of 100: higher than 4% of 399 peers (All). weak.

Rank 7 of 100: higher than 7% of 47 peers (Sector). weak.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

−5.4% per year

Rank 7 of 100: higher than 7% of 375 peers (All). weak.

Rank 5 of 100: higher than 5% of 46 peers (Sector). weak.

Median Health Care: +9.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 0 of 1 met · 6 without data

  • not met: Pays a dividend no dividend per share reported for the last fiscal year
  • no data: Payout ratio at most 60% of earnings pays no dividend
  • no data: Dividend paid in each of the last 5 fiscal years pays no dividend
  • no data: Dividend per share never lowered in the last 5 fiscal years pays no dividend
  • no data: Dividend per share higher than 5 years ago pays no dividend
  • no data: Free cash flow per share covers the dividend pays no dividend
  • no data: Dividends paid over the last 5 years covered by free cash flow pays no dividend

Financial strength 5 of 6 met

  • not met: Piotroski F-Score at least 7 of 9 5 of 9
  • met: Long-term debt no higher than equity 0.34
  • met: Current assets cover current liabilities 2.68
  • met: Positive equity 18.3B USD
  • met: In 5 years, share count up by at most 5% −8.8%
  • met: Free cash flow positive in the last fiscal year 2.1B USD
Piotroski F-Score

5 of 9 Fiscal year 2025

Rank 22 of 100: higher than 22% of 310 peers (All). weak.

Rank 17 of 100: higher than 17% of 47 peers (Sector). weak.

Median Health Care: 6.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

0.34 at fiscal year end

Rank 74 of 100: lower than 74% of 486 peers (All). strong.

Rank 77 of 100: lower than 77% of 50 peers (Sector). strong.

Median Health Care: 0.66

Long-term financial debt divided by equity.

Liquidity (current ratio)

2.68 at fiscal year end

Rank 82 of 100: higher than 82% of 513 peers (All). strong.

Rank 77 of 100: higher than 77% of 63 peers (Sector). strong.

Median Health Care: 1.58

Current assets divided by current liabilities.

Change in share count

−8.8% in 5 years

Rank 71 of 100: lower than 71% of 507 peers (All). strong.

Rank 72 of 100: lower than 72% of 59 peers (Sector). strong.

Median Health Care: −4.3%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • not met: Return on assets higher than the prior year
  • met: Operating cash flow higher than net income
  • met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • not met: No additional shares (diluted share count did not rise)
  • not met: Gross margin higher than the prior year
  • not met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light red: Revenue shrank over 5 years (−6.0% per year).
  • Light red: Net income (total) shrank over 5 years (−20.2% per year); per share −18.7% per year.
  • Light yellow: Net margin 13.1%, below the sector median (13.9%).
  • Light green: Debt not higher than usual in the sector.
  • Light green: Profit in each of the last 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 11.4B USD · Net income 3.7B USD · Net margin 32.3%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 12.3B USD · Net income 2.5B USD · Net margin 20.7%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 13.5B USD · Net income 4.4B USD · Net margin 32.9%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 14.4B USD · Net income 5.9B USD · Net margin 41.0%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 13.4B USD · Net income 4.0B USD · Net margin 29.8%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 11.0B USD · Net income 1.6B USD · Net margin 14.2%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 10.2B USD · Net income 3.0B USD · Net margin 29.9%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 9.8B USD · Net income 1.2B USD · Net margin 11.8%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 9.7B USD · Net income 1.6B USD · Net margin 16.9%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 9.9B USD · Net income 1.3B USD · Net margin 13.1%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 9.9B USD · Net income 1.3B USD · Net margin 13.1%

How has it gone since the last annual report?

Trailing 12 months and quarters

Revenue in the quarter to Sep 2026 +10.6% vs. the same quarter a year earlier; grown for 3 quarters in a row.

Revenue 12 months vs. prior 12
+2.3%
12 months: 10.3B USD · Fiscal year 2025: +2.2%
Net margin 12 months
3.4%
Fiscal year 2025: 13.1%
Free cash flow margin 12 months
20.1%
Fiscal year 2025: 20.7%
More depth

Calculation of the 12 months to Sep 30, 2026

  • Revenue: fiscal year to Dec 31, 2025 9.9B USD + year to date to Sep 30, 2026 8.0B USD − same period a year earlier to Sep 30, 2025 7.6B USD = 10.3B USD
  • Net income: fiscal year to Dec 31, 2025 1.3B USD + year to date to Sep 30, 2026 396.4M USD − same period a year earlier to Sep 30, 2025 1.3B USD = 347.5M USD
  • Operating cash flow: fiscal year to Dec 31, 2025 2.2B USD + year to date to Sep 30, 2026 1.7B USD − same period a year earlier to Sep 30, 2025 1.7B USD = 2.2B USD
  • Capital expenditure: fiscal year to Dec 31, 2025 153.8M USD + year to date to Sep 30, 2026 132.5M USD − same period a year earlier to Sep 30, 2025 109.9M USD = 176.4M USD
By quarter (latest first, amounts in USD)
QuarterRevenuevs. year agoNet incomeMargin
Jul–Sep 262.8B+10.6%−20.6M−0.7%
Apr–Jun 262.7B+3.4%97.5M3.6%
Jan–Mar 262.5B+1.9%319.5M12.9%
Oct–Dec 25*2.3B−7.1%−48.9M−2.1%
Jul–Sep 252.5B+2.8%466.5M18.4%
Apr–Jun 252.6B+7.3%634.8M24.0%
Jan–Mar 252.4B+6.1%240.5M9.9%
Oct–Dec 24*2.5B+2.9%266.7M10.9%

Trailing 12 months = last fiscal year + the period since the start of the current fiscal year − the same period a year earlier, each from the first filing. P/E, PEG and the quality checks still use the last fiscal year.

Each quarter is compared with the same quarter a year earlier.

* derived: fiscal year minus the first 9 months.

As of: 12 months to Sep 30, 2026, filed on Oct 28, 2026 · Source: SEC filings (10-Q, 10-K)

Does the profit arrive as cash?

Earnings quality

Profit is backed by cash; interest is well covered.

Cash flow ÷ profit
1.71x
backed from 1.0 · 3 years: 1.62x
Interest coverage
6.8x
well covered from 5 · EBIT, derived · 3 years: 7.2x
Tax rate
16.9%
for information only · 3 years: 14.1%
More depth

Calculation for fiscal year 2025

  • Operating cash flow 2.2B USD ÷ Net income 1.3B USD = 1.71x
  • EBIT, derived (profit before tax plus interest expense) 1.8B USD ÷ Interest expense 267.5M USD = 6.8x
  • Taxes 263.6M USD ÷ profit before tax 1.6B USD = 16.9%
By fiscal year
FYCash flow ÷ profitInterest coverageTax rate
20251.71x6.8x16.9%
20241.76x8.6x14.4%
20231.33x6.3x10.4%
20220.47x15.6x17.6%
20212.11x11.2x3.0%

How it is rated: cash flow ÷ profit from 1.0 “backed by cash”, below 0.8 “profit well above the cash coming in”; interest coverage from 5 “well covered”, below 2 “thinly covered”. The tax rate is only shown.

Cash flow ÷ profit uses group profit incl. minority interests, because cash flow also covers the whole group. Profit before tax as reported to the SEC, otherwise approximated. “3 years” = sums of the last three fiscal years – only if every year is reported and the figures have the same origin; for cash flow only with a profit in every year.

As of fiscal year 2025 · Source: SEC filings

How even were the last years?

Consistency

In 10 fiscal years no loss year and 5 years with lower revenue.

Loss years
0 of 10
net income below zero
Years with lower revenue
5 of 10
revenue below the prior year
Net margin range
29.2 percentage points
from 11.8% to 41.0%
Net margin by fiscal year · ▾ revenue below the prior year
More depth
By fiscal year
FYRevenue vs. prior yearNet margin
2025+2.2%13.1%
2024−1.6%16.9%
2023−3.3%11.8%
2022−7.4%29.9%
2021−18.3%14.2%
2020−6.5%29.8%
2019+6.9%41.0%
2018+9.6%32.9%
2017+7.2%20.7%
2016+6.4%32.3%

Loss year: net income below zero. Lower revenue: revenue below the prior year. Range: highest minus lowest net margin; margins beyond ±200% do not count. No score – only the reported figures.

As of fiscal years 2016–2025 · Source: SEC filings

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 75.7 USD gross profit and 13.1 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue9.9B USD100.0%
Gross profit7.5B USD75.7%
Cost of revenue2.4B USD24.3%
Net income1.3B USD13.1%
Research & development1.8B USD18.0%
Interest expense267.5M USD2.7%
Taxes263.6M USD2.7%
Remaining costs & other3.9B USD39.3%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The operating margin fell in 5 years from 45.0% to 25.9%.

Gross marginOperating marginNet margin
  1. Fiscal year 2016: Gross margin 87.1% · Operating margin 45.0% · Net margin 32.3%
  2. Fiscal year 2017: Gross margin 86.7% · Operating margin 43.5% · Net margin 20.7%
  3. Fiscal year 2018: Gross margin 86.5% · Operating margin 43.8% · Net margin 32.9%
  4. Fiscal year 2019: Gross margin 86.4% · Operating margin 49.0% · Net margin 41.0%
  5. Fiscal year 2020: Gross margin 86.6% · Operating margin 33.8% · Net margin 29.8%
  6. Fiscal year 2021: Gross margin 80.8% · Operating margin 25.9% · Net margin 14.2%
  7. Fiscal year 2022: Gross margin 77.6% · Operating margin not available · Net margin 29.9%
  8. Fiscal year 2023: Gross margin 74.2% · Operating margin not available · Net margin 11.8%
  9. Fiscal year 2024: Gross margin 76.1% · Operating margin not available · Net margin 16.9%
  10. Fiscal year 2025: Gross margin 75.7% · Operating margin not available · Net margin 13.1%

Returns

Return on equity fell in 5 years from 37.4% to 7.1%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 30.5% · Return on assets 16.2%
  2. Fiscal year 2017: Return on equity 20.1% · Return on assets 10.7%
  3. Fiscal year 2018: Return on equity 34.0% · Return on assets 17.5%
  4. Fiscal year 2019: Return on equity 44.1% · Return on assets 21.6%
  5. Fiscal year 2020: Return on equity 37.4% · Return on assets 16.3%
  6. Fiscal year 2021: Return on equity 14.3% · Return on assets 6.5%
  7. Fiscal year 2022: Return on equity 22.7% · Return on assets 12.4%
  8. Fiscal year 2023: Return on equity 7.8% · Return on assets 4.3%
  9. Fiscal year 2024: Return on equity 9.8% · Return on assets 5.8%
  10. Fiscal year 2025: Return on equity 7.1% · Return on assets 4.4%

Equity and long-term debt

The equity ratio rose in 5 years from 43.5% to 62.0%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 12.1B USD · Long-term debt 6.5B USD
  2. Fiscal year 2017: Equity 12.6B USD · Long-term debt 5.9B USD
  3. Fiscal year 2018: Equity 13.0B USD · Long-term debt 5.9B USD
  4. Fiscal year 2019: Equity 13.3B USD · Long-term debt 4.5B USD
  5. Fiscal year 2020: Equity 10.7B USD · Long-term debt 7.4B USD
  6. Fiscal year 2021: Equity 10.9B USD · Long-term debt 6.3B USD
  7. Fiscal year 2022: Equity 13.4B USD · Long-term debt 6.3B USD
  8. Fiscal year 2023: Equity 14.8B USD · Long-term debt 6.9B USD
  9. Fiscal year 2024: Equity 16.7B USD · Long-term debt 6.3B USD
  10. Fiscal year 2025: Equity 18.3B USD · Long-term debt 6.3B USD

Liquidity (current ratio)

The current ratio rose in 5 years from 1.84 to 2.68.

Current ratio
  1. Fiscal year 2016: Current ratio 2.55
  2. Fiscal year 2017: Current ratio 2.34
  3. Fiscal year 2018: Current ratio 2.32
  4. Fiscal year 2019: Current ratio 1.72
  5. Fiscal year 2020: Current ratio 1.84
  6. Fiscal year 2021: Current ratio 1.83
  7. Fiscal year 2022: Current ratio 2.99
  8. Fiscal year 2023: Current ratio 2.00
  9. Fiscal year 2024: Current ratio 1.35
  10. Fiscal year 2025: Current ratio 2.68

Cash flow

Free cash flow fell in 5 years from 3.8B USD to 2.1B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 4.5B USD · Capital expenditure 616.1M USD · Free cash flow 3.9B USD
  2. Fiscal year 2017: Operating cash flow 4.6B USD · Capital expenditure 867.4M USD · Free cash flow 3.7B USD
  3. Fiscal year 2018: Operating cash flow 6.2B USD · Capital expenditure 770.6M USD · Free cash flow 5.4B USD
  4. Fiscal year 2019: Operating cash flow 7.1B USD · Capital expenditure 514.5M USD · Free cash flow 6.6B USD
  5. Fiscal year 2020: Operating cash flow 4.2B USD · Capital expenditure 424.8M USD · Free cash flow 3.8B USD
  6. Fiscal year 2021: Operating cash flow 3.6B USD · Capital expenditure 258.1M USD · Free cash flow 3.4B USD
  7. Fiscal year 2022: Operating cash flow 1.4B USD · Capital expenditure 240.3M USD · Free cash flow 1.1B USD
  8. Fiscal year 2023: Operating cash flow 1.5B USD · Capital expenditure 277.0M USD · Free cash flow 1.3B USD
  9. Fiscal year 2024: Operating cash flow 2.9B USD · Capital expenditure 153.7M USD · Free cash flow 2.7B USD
  10. Fiscal year 2025: Operating cash flow 2.2B USD · Capital expenditure 153.8M USD · Free cash flow 2.1B USD

Share count

The share count fell in 5 years by 8.8% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 218.8M
  2. Fiscal year 2017: Diluted share count 213.0M
  3. Fiscal year 2018: Diluted share count 205.3M
  4. Fiscal year 2019: Diluted share count 187.4M
  5. Fiscal year 2020: Diluted share count 161.3M
  6. Fiscal year 2021: Diluted share count 149.6M
  7. Fiscal year 2022: Diluted share count 146.0M
  8. Fiscal year 2023: Diluted share count 145.6M
  9. Fiscal year 2024: Diluted share count 145.9M
  10. Fiscal year 2025: Diluted share count 147.1M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Metrics chart

Up to three metrics stacked over the same fiscal years – so you see at a glance whether they rise together or drift apart. Point at a year to read it in every panel.

Metrics, up to 3 – to switch, deselect one first

Premium Line of a second stock for comparison

No annual figures for this stock: Dividend per share, Payout ratio (earnings), Payout ratio (free cash flow).

Source: SEC filings, fiscal years up to Dec 31, 2025. The same figures as in the sections of this page, per fiscal year as first reported. Describes the reported figures – not investment advice.

How reliable is the dividend?

Dividend at a glance

The company pays no dividend.

As of fiscal year 2025 · Source: SEC filings

Valued higher or lower than usual?

Valuation against its own history

The P/E is above its own median of the 5 fiscal years before.

With a free account you can see how far – and the same for P/S and price/free cash flow, with the calculation. Sign up free

Source: SEC filings and our daily candles

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
none pays no dividend
To shareholders (4 years)
2.6B USD 100% through repurchases
Share count over 5 years
−8.8% fewer shares – each share is a larger stake

What goes back to shareholders

Over 4 years, 2.6B USD went back to shareholders, 100% of it through share repurchases. That is 30% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid not available · Share repurchases 1.0B USD · New shares issued (including employee plans) not available · Free cash flow 3.9B USD
  2. Fiscal year 2017: Dividends paid not available · Share repurchases 1.4B USD · New shares issued (including employee plans) not available · Free cash flow 3.7B USD
  3. Fiscal year 2018: Dividends paid not available · Share repurchases 4.4B USD · New shares issued (including employee plans) not available · Free cash flow 5.4B USD
  4. Fiscal year 2019: Dividends paid not available · Share repurchases 5.9B USD · New shares issued (including employee plans) not available · Free cash flow 6.6B USD
  5. Fiscal year 2020: Dividends paid not available · Share repurchases 6.7B USD · New shares issued (including employee plans) not available · Free cash flow 3.8B USD
  6. Fiscal year 2021: Dividends paid not available · Share repurchases 1.8B USD · New shares issued (including employee plans) not available · Free cash flow 3.4B USD
  7. Fiscal year 2022: Dividends paid not available · Share repurchases 750.0M USD · New shares issued (including employee plans) not available · Free cash flow 1.1B USD
  8. Fiscal year 2023: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 1.3B USD
  9. Fiscal year 2024: Dividends paid not available · Share repurchases 0.0 USD · New shares issued (including employee plans) not available · Free cash flow 2.7B USD
  10. Fiscal year 2025: Dividends paid not available · Share repurchases not available · New shares issued (including employee plans) not available · Free cash flow 2.1B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Biogen next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison BIIB, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
AMGN Amgen 36.8B USD +7.6%67.2%24.7%21.0%89.1%9.6%22.0%7/9
MDT Medtronic 36.4B USD +3.8%65.0%17.8%13.2%9.7%53.2%14.9%7/9
GILD Gilead Sciences 29.4B USD +3.6%78.8%34.0%28.9%37.5%38.5%32.1%8/9
SYK Stryker Corporation 25.1B USD +11.8%64.0%19.5%12.9%14.5%46.9%17.1%6/9
DHR Danaher Corporation 24.6B USD +2.0%59.1%19.1%14.7%6.9%62.9%21.4%7/9
REGN Regeneron Pharmaceuticals 14.3B USD +11.0%–24.9%31.4%14.4%77.1%28.4%–
VRTX Vertex Pharmaceuticals 12.0B USD +14.1%86.2%34.8%32.9%21.2%72.8%26.6%–
ISRG Intuitive Surgical 10.1B USD +18.2%66.0%29.3%28.4%16.0%87.1%24.7%–
BIIB Biogen this stock 9.9B USD −6.0%75.7%–13.1%7.1%62.0%20.7%5/9
Median of the sector 27 symbols 44.3B USD +8.4%67.9%18.0%13.2%13.6%38.5%15.8%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Compare with the closest peer in the sector BIIB next to ISRG – quality checks, metrics and depth side by side.

Figures of the last fiscal year from SEC annual reports (peers as of Nov 22, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 26 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light red: shrinking

−6.0% per year, last 5 years

Sector Health Care: median +8.5% (25 symbols)

What does this mean? Revenue: over 5 years it fell by 6.0% per year on average. The median company in the sector reached +8.5% per year.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light red: shrinking

−20.2% per year, last 5 years

Sector Health Care: median +5.5% (20 symbols)

per share: −18.7% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it fell by 20.2% per year on average. The median company in the sector reached +5.5% per year.

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light yellow: below sector

13.1% last fiscal year

Sector Health Care: median 13.9% (26 symbols)

What does this mean? Of every 100 USD in revenue, 13.07 USD remained as profit – less than the median company in the sector (13.9%). Five years ago the margin was 29.8%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light green: lower than sector

0.39 latest balance sheet

Sector Health Care: median 0.66 (19 symbols)

What does this mean? For every 1 USD of equity there is 0.39 USD of financial debt – no more than the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light gray: none found

– Dividend / earnings per share

Sector Health Care: median 56% (16 symbols)

What does this mean? The loaded SEC filings of the last two fiscal years contain no dividend per share. Either the company pays none, or it reports it under a different tag.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light green: profit every year

10 of 10 fiscal years with a profit

What does this mean? In 10 of the last 10 fiscal years the bottom line showed a profit. There were no losses in this period.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
9.9B USD
Revenue vs. prior year
+2.2%
Net income (FY)
1.3B USD
Net income vs. prior year
−20.8%
EPS (FY)
8.79 USD
Superinvestors holding
3 of 26
Fiscal year to Dec 31, 2025 · 10-K filed Feb 6, 2026 · Balance sheet Sep 30, 2026 (filed Oct 28, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). Superinvestors: 26 tracked investors per 13F filing (as of quarter end, filed up to 45 days later); weight and change per investor in the card “Which superinvestors hold …?”.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 9.9B1.3B 13.1% 8.79 – –
2024Dec 31, 2024 9.7B1.6B 16.9% 11.18 – –
2023Dec 31, 2023 9.8B1.2B 11.8% 7.97 – –
2022Dec 31, 2022 10.2B3.0B 29.9% 20.87 – –
2021Dec 31, 2021 11.0B1.6B 14.2% 10.40 – –
2020Dec 31, 2020 13.4B4.0B 29.8% 24.80 – –
2019Dec 31, 2019 14.4B5.9B 41.0% 31.42 – –
2018Dec 31, 2018 13.5B4.4B 32.9% 21.58 – –
2017Dec 31, 2017 12.3B2.5B 20.7% 11.92 – –
2016Dec 31, 2016 11.4B3.7B 32.3% 16.93 – –
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q3/26Sep 30, 2026 2.8B−20.6M −0.7% −0.14 – –
Q2/26Jun 30, 2026 2.7B97.5M 3.6% 0.66 – –
Q1/26Mar 31, 2026 2.5B319.5M 12.9% 2.15 – –
Q4/25*Dec 31, 2025 2.3B−48.9M −2.1% – – –
Q3/25Sep 30, 2025 2.5B466.5M 18.4% 3.17 – –
Q2/25Jun 30, 2025 2.6B634.8M 24.0% 4.33 – –
Q1/25Mar 31, 2025 2.4B240.5M 9.9% 1.64 – –
Q4/24*Dec 31, 2024 2.5B266.7M 10.9% – – –
Q3/24Sep 30, 2024 2.5B388.5M 15.8% 2.66 – –
Q2/24Jun 30, 2024 2.5B583.6M 23.7% 4.00 – –
Q1/24Mar 31, 2024 2.3B393.4M 17.2% 2.70 – –
Q4/23*Dec 31, 2023 2.4B249.7M 10.5% – – –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Information only – does not affect the other analysis methods, not investment advice.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $00 people $0
6 months $00 people $239.7K1 person −$239.7K
12 months $585.11 person $905.4K2 people −$904.8K

Latest transactions

  • Aug 4, 2026 Minor Lloyd Director Open-market sale · 10b5-1 plan 593 shares · $119.2K · SEC
  • Aug 3, 2026 Minor Lloyd Director Open-market sale · 10b5-1 plan 593 shares · $120.6K · SEC
  • Feb 12, 2026 Murphy Nicole Officer Open-market purchase 3 shares · $585.1 · SEC
  • Feb 9, 2026 Singhal Priya Officer Open-market sale · 10b5-1 plan 2,660 shares · $531.5K · SEC
  • Feb 2, 2026 Singhal Priya Officer Open-market sale · 10b5-1 plan 748 shares · $134.1K · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Which superinvestors hold Biogen?

All superinvestor portfolios

3 of 26 tracked superinvestors report a position.

Superinvestors with a position in Biogen, weight in each portfolio
InvestorWeight in portfoliovs. previous quarterAs of
Paul Tudor Jones Tudor Investment Corp < 0.1% new Q3 2026
Renaissance Technologies < 0.1% −98.1% reduced Q3 2026
Steve Cohen Point72 Asset Management < 0.1% −96.3% reduced Q3 2026

Source: 13F filing with the US Securities and Exchange Commission, latest filing dated Nov 16, 2026. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

Trend score –

We do not calculate a trend score for symbols in the extended universe.

Volatility and trend strength

ADX 14 (trend strength)–
Price change 60 days–

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on BIIB yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: BIIB

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly, stocks twice a day, precious metals every 4 hours on trading days, extended universe on weekdays after the close (daily candles) – not in real time.

↑ ↓ select · Enter open · Esc close